Facebook-f Twitter Instagram Podcast Youtube Tiktok Linkedin-in Pinterest Envelope Share
CLICK HERE TO SHARE YOUR STORY!
  • About
    • Meet Our Contributors
    • Meet Our Partners
    • Meet the Patient Worthy Team
    • Collaborative Content On Patient Worthy
  • Diseases
  • Share Your Story
    • Patient Worthy Content Submission Guidelines
    • Patient Worthy Writing Prompts
    • Submit Your Story
    • Patient Stories
  • Resources
    • Library
    • Events
    • Patient Worthy FAQs
  • Podcast
  • Contact
Menu
  • About
    • Meet Our Contributors
    • Meet Our Partners
    • Meet the Patient Worthy Team
    • Collaborative Content On Patient Worthy
  • Diseases
  • Share Your Story
    • Patient Worthy Content Submission Guidelines
    • Patient Worthy Writing Prompts
    • Submit Your Story
    • Patient Stories
  • Resources
    • Library
    • Events
    • Patient Worthy FAQs
  • Podcast
  • Contact
  • Join PW

Blog

  1. Home>
  2. 2019>
  3. January>
  4. 4>
  5. Lupus Nephritis>
  6. Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy

Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy

Trudy Horsting

  • January 4, 2019
  • C3 Glomerulopathy, IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy

Apellis Pharmaceuticals has just announced that they have received Orphan Drug Designation from the FDA for APL-2, a C3 complement inhibitor. The company is currently investigating the drug as a potential treatment for C3 glomerulopathy (C3G).

C3G causes an accumulation of C3 within the glomeruli. This is the part of the kidney which handles blood filtration and an excessive amount of C3 within it can ultimately lead to end-stage renal disease. Currently, there are no approved treatments for C3G and about half of patients advance to end-stage within 10 years of the time they receive their diagnosis. APL-2 works to inhibit C3, and Apellis believes it may be an effective treatment for this condition.

Apellis is currently working on a Phase 2 trial examining the effect of APL-2 as a treatment for four different types of glomerular conditions including C3G, lupus nephritis, membranous nephropathy, and igA nepropathy.

Orphan Drug Designation

Orphan Drug Designation for APL-2 provides Apellis with consultation by the FDA on their trial designs, fee exemptions/reductions, 7 years market exclusivity within the United States, and could potentially expedite the drugs development. This designation is provided to novel treatments which the FDA believes could aid those living with rare conditions.

Apellis is excited about their drugs new designation because it indicates that the FDA recognizes the potential it has to help patients. There is truly an unmet need for C3G and this drug could be life-changing for those affected by the condition. So far in studies APL-2 has been well tolerated and there have been no significant infections reported.

Fingers crossed that the current Phase 2 trial continues to show positive results for this new treatment and that the drug will receive FDA approval soon.

You can read more about this drug and its latest developments here.


What are your thoughts on this new potential treatment for C3 Glomerulopathy? Share your stories, thoughts, and hopes with the Patient Worthy community!

Trudy Horsting

Trudy Horsting

All Posts

Featured


Picture of Family


Metastatic Breast Cancer: Navigating Grief


Picture of Ralph Family walking


Rethinking What It Means to Live With Acromegaly


Illustration of mentor program members


The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

CLICK HERE TO SHARE YOUR STORY!
We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.
Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Partner With Us
Submit a Story

Keep Up to Date

Subscribe to Our Newsletter
Check Out Rare Events
Get Inspired By Our Memes

Learn More

About Us
Rare Diseases and Conditions
Terms of Use
Privacy Notice
Privacy Policy for CA Residents
EU/UK Privacy Notice
Data Privacy Framework: Consumer Privacy Policy
Consumer Health Data Privacy Policy
Cookie Notice

Facebook-f Twitter Instagram Podcast Youtube Tiktok Linkedin-in Pinterest Envelope

© Copyright 2024 Patient Worthy

Sign Up With a Patient Worthy Account and Share Your Rare Story

- OR -

Sign Up For Our Patient Panel

Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.

More Info

We're Happy You're Here!

What best describes you when it comes to rare disease? (check all that apply)

What rare disease(s)/conditions are most important to you?

Visit Home Page or

Thank you for signing up for a Patient Worthy Account!

Have a rare disease story to share? Let us know

Share Story

- OR -

Sign Up For Our Patient Panel

Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.

More Info